Chapter 3 · Moat
Not one drug —
a platform that
makes many.
mRNA is a programmable technology. COVID proved it works; the bet is it works for much more.
↓ scroll to read
✦ The bottom line
Moderna's moat is its mRNA platform: a programmable way to instruct the body to make a protein. Change the genetic 'code' and you get a different vaccine or therapy — COVID, RSV, flu, even individualized cancer vaccines — using the same core technology, manufacturing, and IP. COVID was the proof. The platform is the asset.
↓ the brief below
✦ Teach me
Why a platform is a different kind of moat
Most drug companies' moats are individual approved products. A platform moat is broader: one underlying technology that can spawn many products. If it works, each new program is faster and cheaper than starting from scratch, and the accumulated know-how, patents, and factories are hard to copy.
The catch: a platform is only as valuable as the products it actually ships. COVID and RSV prove the platform can produce winners. The open question is how many more — and how big.
Wall Street calls this
Platform technology / IP moat
It's why Moderna can be worth a lot while losing money: you're valuing the *future output* of a proven platform, not this year's sales. That's also why the pipeline (Chapter 5) matters more than the income statement.
From the 10-K · the platform's output so far
...products—Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our vaccine against respiratory syncytial virus (RSV)).
↳ Read it as proof-of-platform: the same mRNA technology already yielded multiple approved vaccines across different diseases. That repeatability — not any one product — is the moat. The next test is whether it extends to cancer and flu.
Source · 10-K · Business — Commercial Products · FY2025 · Filed Feb 20, 2026